State of Michigan Retirement System Sells 7,300 Shares of Edwards Lifesciences Corporation $EW

State of Michigan Retirement System trimmed its stake in Edwards Lifesciences Corporation (NYSE:EW) by 2.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 257,351 shares of the medical research company’s stock after selling 7,300 shares during the period. State of Michigan Retirement System’s holdings in Edwards Lifesciences were worth $21,939,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of EW. JPL Wealth Management LLC bought a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at approximately $25,000. True Wealth Design LLC lifted its stake in shares of Edwards Lifesciences by 251.5% in the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 259 shares during the last quarter. Hantz Financial Services Inc. lifted its stake in shares of Edwards Lifesciences by 76.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 164 shares during the last quarter. Dorato Capital Management bought a new stake in shares of Edwards Lifesciences in the 4th quarter valued at approximately $29,000. Finally, Rakuten Securities Inc. lifted its stake in shares of Edwards Lifesciences by 413.7% in the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 302 shares during the last quarter. 79.46% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Stifel Nicolaus set a $110.00 target price on Edwards Lifesciences and gave the company a “buy” rating in a research note on Tuesday, January 20th. BTIG Research upped their target price on Edwards Lifesciences from $98.00 to $100.00 and gave the company a “buy” rating in a research note on Friday. Wells Fargo & Company upped their target price on Edwards Lifesciences from $96.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday, February 11th. UBS Group reaffirmed a “neutral” rating and set a $94.00 target price on shares of Edwards Lifesciences in a research note on Wednesday, February 4th. Finally, Evercore reaffirmed an “outperform” rating and set a $93.00 target price on shares of Edwards Lifesciences in a research note on Friday. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $95.65.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $80.98, for a total transaction of $82,518.62. Following the transaction, the vice president directly owned 33,934 shares in the company, valued at $2,747,975.32. This trade represents a 2.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 24,000 shares of the firm’s stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $83.84, for a total value of $2,012,160.00. Following the transaction, the vice president owned 21,266 shares in the company, valued at $1,782,941.44. The trade was a 53.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 86,058 shares of company stock worth $7,118,636 in the last ninety days. 0.31% of the stock is owned by company insiders.

Edwards Lifesciences Trading Down 0.8%

EW opened at $83.51 on Tuesday. The stock’s 50 day moving average price is $81.86 and its 200-day moving average price is $82.35. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $87.89. The stock has a market cap of $48.15 billion, a price-to-earnings ratio of 45.63, a P/E/G ratio of 2.18 and a beta of 0.95.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 14.45%. The firm had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. During the same quarter in the previous year, the firm posted $0.64 earnings per share. The company’s revenue was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, equities analysts forecast that Edwards Lifesciences Corporation will post 2.98 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.